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Abstract
Introduction: Understanding the relationship between subsequent-line therapies and overall 
survival (OS) is important for maximizing OS for patients with hepatocellular carcinoma. Ob-
jective: In this post hoc analysis, we investigated OS in lenvatinib- and sorafenib-treated pa-
tients from the REFLECT study, who then received subsequent anticancer medication during 
the survival follow-up period. Methods: The follow-up period commenced at the first off-
treatment visit after stopping the study medication and continued until study termination, 
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withdrawal of consent, or death. OS and objective response rate were calculated for patients 
who did or did not receive poststudy anticancer medication for both treatment arms, as well 
as for the overall cohort. We investigated the subset of patients who responded to first-line 
treatment and subsequently received anticancer medication. Results: The OS for patients ini-
tially randomized to first-line lenvatinib (versus first-line sorafenib) and who then received any 
subsequent anticancer medication was 20.8 vs. 17.0 months (hazard ratio [HR] 0.87; 95% CI 
0.67–1.14). The OS for patients who initially received first-line lenvatinib (versus first-line 
sorafenib) and who did not receive any subsequent anticancer medication was 11.5 vs. 9.1 
months (HR 0.90; 95% CI 0.75–1.09). Responders to first-line lenvatinib who received subse-
quent medication had a median OS of 25.7 months (95% CI 18.5–34.6); responders to first 
line-sorafenib who received subsequent medication had a median OS of 22.3 months (95% CI 
14.6–not evaluable). Conclusions: In this post hoc analysis of all patients in the REFLECT study 
who received subsequent anticancer medication, OS was increased compared with patients 
who did not receive any subsequent anticancer medication. In a subset analysis of responders 
who had received subsequent anticancer medication, use of first-line lenvatinib led to a slight-
ly longer median OS; more research is needed on the benefits of using first-line lenvatinib 
compared with sorafenib. © 2019 The Author(s)
Published by S. Karger AG, Basel
IntroductionHepatocellular carcinoma (HCC) is one of the most common cancers worldwide, with about 841,000 diagnoses and 782,000 deaths per year [1]. It is the most common form of liver cancer and is primarily associated with chronic infections by hepatitis B and C viruses. In 2015, 257 million people worldwide were reported as having the hepatitis B virus and 71 million people had the hepatitis C virus [2]. These viruses often lead to cirrhosis, which limits treatment options for HCC [3, 4]. Initially, sorafenib was the only first-line systemic therapy that improved overall survival (OS) for unresectable HCC (uHCC) [4, 5], until the recent (2018) approval of lenvatinib [6, 7]. Lenvatinib is an oral multikinase inhibitor targeting both vascular endothelial growth factor receptors 1–3 and fibroblast growth factor receptors 1–4, 
in addition to platelet-derived growth factor receptor α, RET, and KIT [8–11]. 
REFLECT was a randomized, open-label, phase 3 study that compared the efficacy and safety of lenvatinib versus sorafenib in first-line treatment of patients with uHCC [6]. Lenvatinib demonstrated a treatment effect on OS, statistically confirmed by noninferiority to sorafenib (the 
primary end point of median OS was 13.6 vs. 12.3 months; hazard ratio [HR] 0.92; 95% CI 0.79–1.06) [6]. Lenvatinib resulted in statistically significant improvements in the secondary end 
points of progression-free survival (PFS), time to progression, and objective response rate (ORR) versus sorafenib (tested sequentially) [6]. Based on the outcomes from REFLECT, lenvatinib became the first agent approved in the first-line treatment setting for uHCC in over a decade [6].The recent availability of new treatment options in first- and subsequent-line therapies has shifted the treatment paradigm for HCC, resulting in questions regarding appropriate medi-cation choices and the timing and sequencing of anticancer therapies. There are relatively few studies directly examining the relationship between OS and subsequent-line therapies [12–17].Understanding the relationship between subsequent-line therapies and OS is important 
for maximizing OS for patients with HCC. Therefore, in this post hoc analysis, we evaluated OS following first-line treatment with lenvatinib or sorafenib in patients with uHCC from 
REFLECT who received subsequent anticancer medication during the survival follow-up period. We also assessed the subset of patients who responded to lenvatinib or sorafenib 
during REFLECT, and subsequently received other systemic anticancer medication(s).
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Methods
PatientsBriefly, eligible patients were ≥18 years of age and had histologically or cytologically uHCC with 1 or more measurable target lesions. Patients had Barcelona Clinic Liver Cancer stage B or C, Child-Pugh class A, 
and an Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0 or 1. Controlled blood pressure (≤150/90 mm Hg) and adequate liver, bone marrow, blood, renal, and pancreatic functions were 
required. Exclusion criteria included 50% or higher liver occupation, clear bile duct invasion, invasion at the 
main portal vein (Vp4), or previous systemic therapy for HCC. Full patient eligibility criteria were previously published [6].This study (NCT01761266) was conducted in accordance with the Declaration of Helsinki, all relevant 
Institutional Review Boards, and local laws. All patients provided written informed consent.
Study Design and Treatment
REFLECT was a phase 3, multicenter, randomized, open-label, noninferiority study comparing lenva-tinib to sorafenib in patients with uHCC [6]. Patients were randomized 1: 1 to receive either lenvatinib or sorafenib [6]. Treatment cycles were 28 days in length. Lenvatinib (Eisai Inc., Woodcliff Lake, NJ, USA) was administered orally once daily at a dosage of either 12 mg/day (for baseline patient bodyweight ≥60 kg) or 8 mg/day (for baseline patient bodyweight < 60 kg). In the case of lenvatinib-related adverse events, the dose could be reduced by increments of 4 mg to a minimum dosage of 4 mg every other day. Sorafenib (Bayer, 
Leverkusen, Germany) 400 mg was administered orally twice daily. Modifications to sorafenib dosages were allowed based on regional prescribing information [6]. 
First-line treatment continued until disease progression, intolerable adverse events, or withdrawal of consent. The study follow-up period commenced at the first off-treatment visit (within 30 days of discon-tinuing the study drug for any reason) and continued until sponsor study termination, withdrawal of consent, or death [6]. All poststudy systemic anticancer therapies were reported until death or data cutoff (November 13, 2016) and were captured as part of the survival follow-up period.
Study Objectives 
The primary end point was OS, as measured from randomization to patient death from any cause. Patients remaining alive at the end of the study were censored at data cutoff [6]. Secondary end points were 
PFS, time to progression, ORR, quality-of-life measurements, and plasma pharmacokinetics for lenvatinib [6]. These end points have previously been reported [6].
Post Hoc Subgroup Analyses
In this post hoc analysis, we investigated OS in lenvatinib- and sorafenib-treated patients from REFLECT who received subsequent anticancer medication during the survival follow-up period. Patients who received nonsystemic subsequent anticancer treatments (e.g., transcatheter arterial 
chemoembolization) during the survival follow-up period were not excluded from the analysis. All patients who received subsequent systemic anticancer medication during the survival follow-up period were counted in the analysis as patients who received subsequent systemic medication, regardless of other treatments received. All other patients were counted in the analysis as patients who did not receive subse-quent systemic anticancer medication. We also investigated the subset of patients who responded to lenva-
tinib or sorafenib during REFLECT, and subsequently received anticancer medication (includes patients who continued first-line medication and those who transitioned to a different medication) during the 
follow-up period. Responders were defined as patients who achieved either complete or partial tumor 
response as assessed by investigators in accordance with modified Response Evaluation Criteria In Solid 
Tumors (mRECIST), which do not require confirmation of response for randomized trials where ORR is not the primary end point [18]. Safety and tolerability data were not collected during the survival follow-up period.
Statistical Methods
Analyses were conducted for the subgroup of REFLECT patients who received subsequent anticancer 
medication. The HRs for OS were calculated using the Cochran-Mantel-Haenszel method, stratified by inter-
active response system stratification factors (region, macroscopic portal vein invasion, and ECOG PS) and are 
presented with 2-sided 95% CI. Evaluations were performed using SAS version 9 or higher.
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Results
Subsequent Anticancer Medication(s) and Patient Status
Patient dispositions in REFLECT have been previously published [6]. A total of 340 patients were included in this post hoc subgroup analysis. 
Of the 954 patients randomized to receive first-line lenvatinib (n = 478) or sorafenib (n = 476) in REFLECT, 340 received subsequent anticancer medication during the survival 
follow-up period: 156 (32.6%) had received first-line lenvatinib and 184 (38.7%) had received first-line sorafenib (Table 1). Of the patients who received subsequent anticancer medication, 
60 who were randomized to first-line lenvatinib and 63 who were randomized to first-line sorafenib also received subsequent anticancer procedures (excluding radiotherapy). Of the patients who were treated with first-line lenvatinib, the most common subsequent anticancer 
medication was sorafenib (25.3%; Table 1). Of the patients treated with first-line sorafenib, the most common subsequent anticancer medication beyond radiographic progression was 
also sorafenib (11.8%; Table 1). The biggest disparity between the first-line lenvatinib and first-line sorafenib groups was 
the number of patients enrolled in second-line clinical trials and randomized to subsequent 
investigational drugs or placebo: 3.1% of those who had received first-line lenvatinib versus 
9.5% of those who had received first-line sorafenib (Table 1). The specific classes of these agents are unknown.
ECOG PS, Child-Pugh class, and liver function assessments for lenvatinib- and sorafenib-treated patients at the time of treatment discontinuation were similar between treatments (Table 2).
OS for the REFLECT Population
Patients in REFLECT randomized to first-line lenvatinib had a median OS of 13.6 months 
(95% CI 12.1–14.9); patients randomized to first-line sorafenib had a median OS of 12.3 
months (95% CI 10.4–13.9 months; Table 3; Fig. 1, 2a) [6]. These data were previously 
published in Kudo et al. [6].
Table 1. Poststudy medications received by patients during the survival follow-up period
Medications taken during the follow-up period, n (%) First-line lenvatinib(n = 478) First-line sorafenib(n = 476)Patients with any anticancer medication during survival follow-up period 156 (32.6) 184 (38.7)Sorafenib 121 (25.3) 56 (11.8)
Fluorouracil 20 (4.2) 26 (5.5)Cisplatin 18 (3.8) 23 (4.8)Investigational druga 15 (3.1) 45 (9.5)Oxaliplatin 14 (2.9) 22 (4.6)Doxorubicin 7 (1.5) 19 (4.0)Capecitabine 7 (1.5) 11 (2.3)
Gemcitabine 7 (1.5) 14 (2.9)
Cabozantinib 0 (0) 11 (2.3)
a 11 patients who received first-line lenvatinib and 15 patients who received first-line sorafenib went on to receive “investigational immunotherapies” as a subsequent medication.
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OS for Patients Who Received Subsequent Anticancer Medication(s)Approximately one-third of all patients from either treatment group received subse-
quent anticancer medication (Table 3; Fig. 1, 2b). Among patients who received subsequent 
anticancer medication, the median OS for patients randomized to first-line lenvatinib (n = 156) versus first-line sorafenib (n = 184) was 20.8 vs. 17.0 months (HR 0.87; 95% CI 0.67–
1.14; Table 3; Fig. 1, 2b). Among patients who did not receive subsequent anticancer medi-cation (n = 614), the median OS for patients who received first-line lenvatinib versus first-line 
sorafenib was 11.5 vs. 9.1 months (HR 0.90; 95% CI 0.75–1.09).
Table 2. Summary of patient status at treatment discontinuationParameter Lenvatinib(n = 451) Sorafenib(n = 451)
ECOG PS, n (%)012
≥3
165 (36.6)220 (48.8)
42 (9.3)
22 (4.9)
189 (41.9)202 (44.8)
39 (8.6)20 (4.4)Child-Pugh class, n (%)ABC 339 (75.2)97 (21.5)13 (2.9) 345 (76.5)99 (22.0)6 (1.3)ALT, nkat/L median (range)a 533.33 (50–12,100) 650.0 (100–18,417)AST, nkat/L median (range)a 900.0 (167–41,683) 983.0 (217–20,183)ALP, nkat/L median (range)a 2,233.3 (417–30,950) 2,333.3 (467–24,283)
Bilirubin, μmol/L median (range)a 12.8 (2–643) 12.7 (3–408)Albumin, g/L median (range)a 37.0 (19–51) 38.0 (19–52)
a In the Western region, 2 patients from the lenvatinib arm and 1 patient from the sorafenib arm had no data. ALP, alkaline 
phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ECOG PS, Eastern Cooperative Oncology Group performance status.
Table 3. OS comparisons for patients receiving first-line lenvatinib or sorafenib for the overall REFLECT population, for patients who received subsequent anticancer medication, and for patients who responded to first-line medication and then received subsequent anticancer medicationParameter Number of patients Median OS, months (95% CI) HR Lenvatinib vs. Sorafenib 95% CIOverall populationLenvatinib 478 13.6 (12.1–14.9) 0.92 0.79–1.06Sorafenib 476 12.3 (10.4–13.9)
Received subsequent medicationLenvatinib 156 20.8 (15.1–23.5) 0.87 0.67–1.14Sorafenib 184 17.0 (14.4–19.1)
Responded to first-line medication and received subsequent anticancer medicationLenvatinib 43 25.7 (18.5–34.6) NA NASorafenib 16 22.3 (14.6–NE) NA NA
HR, hazard ratio; NA, not applicable; NE, not estimable; OS, overall survival; REFLECT, a Multicenter, 
Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus 
Sorafenib in First-Line Treatment of Subjects with Unresectable Hepatocellular Carcinoma.
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OS for First-Line Treatment Responders
First-line lenvatinib responders who received any subsequent anticancer medication (n = 43) had a median OS of 25.7 months (95% CI 18.5–34.6; Table 3; Fig. 3a). First-line sorafenib responders who received any subsequent anticancer medication (n = 16) had a 
median OS of 22.3 months (95% CI 14.6-not evaluable; Table 3; Fig. 3b). Lenvatinib responders who received subsequent sorafenib treatment (n = 35) had a median OS of 26.2 months (95% 
CI 18.2–34.6; Fig. 4). Only 8 sorafenib responders received poststudy sorafenib treatment; therefore, survival estimates were not performed for this subgroup.
DiscussionThe impact of the multiple recent approvals in the treatment of advanced HCC is chal-
lenging our assumptions on survival in the first-line setting. In REFLECT, lenvatinib had a positive effect on OS and was statistically confirmed to be noninferior to sorafenib, but did 
not show superiority despite its significant improvements in PFS, ORR, and time to progression [6]. Per investigator review using mRECIST, the ORR for lenvatinib was 24.1 vs. 9.2% for sorafenib [6]. A recent (2019) multivariate analysis by Kudo et al. [19] of REFLECT responders 
demonstrated a correlation between objective response and OS, similar to analyses from other large clinical trials in uHCC [20, 21], both by independent review using mRECIST. 
REFLECT study
Patients with uHCC
randomized 1:1 to
first-line lenvatinib or sorafenib
Patients receiving subsequent
anticancer medication
Subset analysis
Lenvatinib (n = 478)
Median OS: 13.6 months
First-line lenvatinib (n = 156)
Median OS: 20.8 months
Sorafenib (n = 476)
Median OS: 12.3 months
First-line sorafenib (n = 184)
Median OS: 17.0 months
Survival follow-up
Fig. 1. OS comparisons for pa-tients receiving first-line lenva-tinib or sorafenib for the overall 
REFLECT population and for pa-tients who received subsequent anticancer medication during the survival follow-up period. OS, 
overall survival; REFLECT, A Mul-ticenter, Randomized, Open-La-bel, Phase 3 Trial to Compare the 
Efficacy and Safety of Lenvatinib 
(E7080) Versus Sorafenib in 
First-Line Treatment of Subjects with Unresectable Hepatocellular Carcinoma; uHCC, unresectable hepatocellular carcinoma.
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This post hoc analysis, based on information captured in the survival follow-up period of 
REFLECT, adds additional support for investigating the importance of treatment sequence on OS. 
Approximately one-third of patients from both treatment arms in REFLECT received subsequent 
anticancer medication and at the time of treatment discontinuation, ECOG PS and liver function 
were similar for patients randomized to either treatment. Despite these similarities, in the subset 
of patients that received subsequent anticancer medication, patients randomized to first-line 
lenvatinib had numerically longer median OS than patients randomized to first-line sorafenib. While the number of first-line responders who received subsequent anticancer medication was 
too small to draw strong conclusions, those randomized to first-line lenvatinib also had longer 
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Fig. 2. Kaplan-Meier estimates of OS for (a) the overall REFLECT population by treatment arm (reprinted 
from Kudo et al. [6], Copyright 2018, with permission from Elsevier) and (b) patients from REFLECT who 
received subsequent anticancer medication by first-line treatment arm. HR, hazard ratio; REFLECT, A Multi-center, Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) 
Versus Sorafenib in First-Line Treatment of Subjects with Unresectable Hepatocellular Carcinoma; OS, over-all survival.
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median OS compared with those randomized to first-line sorafenib. Interestingly, both treatment arms had similar median OS for the overall population. However, there were more patients who received subsequent anticancer medication following first-line sorafenib (n = 184) than patients who received first-line lenvatinib (n = 156), and this imbalance may be the cause of the similar 
OS between treatment arms in the overall population. Regardless of first-line treatment, patients who received subsequent anticancer medication had longer median OS as compared with patients who did not receive subsequent medication.
At the time of the REFLECT study (study period March 1, 2013 – November 13, 2016), currently common therapies such as regorafenib and nivolumab were in clinical trials requiring the failure of first-line sorafenib, which limited second-line investigational agent options for patients receiving first-line lenvatinib. Though approximately 3-fold more patients treated with first line sorafenib went on to participate in clinical trials with investigational 
drugs, patients randomized to first-line lenvatinib who received subsequent medication had 
numerically longer median OS. The majority of patients who received first-line lenvatinib and then subsequent anticancer medication received second-line sorafenib, which was the only 
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Fig. 3. Kaplan-Meier estimates of OS for (a) lenvatinib responders and (b) sorafenib responders who re-
ceived any subsequent anticancer medication. NE, not estimable; OS, overall survival.
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systemic treatment at the time with demonstrated activity in HCC [6]. Therefore, the difference in OS between patients who received first-line lenvatinib or sorafenib followed by subse-quent anticancer medication may be attenuated simply by the requirement for the failure of first-line sorafenib to enter into investigational trials. With the recent approval of many second-line treatment options (regorafenib, nivolumab, 
pembrolizumab, cabozantinib, and ramucirumab) for uHCC [22, 23], it is important to assess treatment patterns for patient benefit. There are many hurdles to getting a patient with uHCC 
to second-line treatment. Disease characteristics, such as ECOG status and poor liver function, can have a significant outcome on trial results, as they can decrease tolerance of the study 
medication and increase the incidence of AEs [24]. 
The study of regorafenib after sorafenib in patients with HCC (RESORCE) was a phase 3 
trial showing that patients with HCC who progressed on sorafenib and were then randomized 
to regorafenib had a median OS of 10.6 months (95% CI 9.1–12.1) compared with 7.8 months 
(6.3–8.8) for those then randomized to a placebo (NCT01774344 [25]). However, patients 
who participated in RESORCE could not have any systemic treatments for HCC prior to sorafenib, and they must have tolerated sorafenib and only discontinued due to disease progression [25]. Additionally, they had to have a Child-Pugh Class A, an ECOG PS of 0 or 1, and a life expectancy of at least 3 months [25]. These criteria may have improved the chance of patients tolerating regorafenib, which then resulted in improved OS [24]. 
The patient population of REFLECT was much more varied, yet the median survival for 
patients randomized to first-line lenvatinib followed by subsequent medication, especially for responders, is the highest reported to date in a phase III trial for uHCC. These data suggest that first-line lenvatinib followed by subsequent systemic anticancer medication could be an important treatment sequence that may lead to longer OS. This sequence may have even greater survival benefits for responders to first-line lenvatinib, though the proportion of responders who received subsequent anticancer medication was small compared with the 
overall REFLECT population. We also recognize that our post hoc analyses are limited – 
patients were not prerandomized to the subsequent medications they received, and there 
could be selection bias confounding the results. Given the exploratory nature of these analyses, the results presented here are descriptive and should be interpreted with caution.
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Fig. 4. Kaplan-Meier estimate of OS for lenvatinib responders who received subsequent sorafenib. OS, over-all survival.
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